You are here

Home » Content

Nikotin Bağımlılığına Karşı Aşılama Yöntemi: Yeni Bir Umut mu?

VACCINATION METHOD AGAINST NICOTINE DEPENDENCE: IS IT A NEW HOPE?

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Drug addiction is a chronically relapsing brain disorder. Smoking cigarette and related disorders are the most preventable cause of death. Nicotine is the principal addictive component of tobac¬co. Nicotine produces a variety of effects in the brain to initiate and maintain tobacco dependence. Neural pathways involved in nicotine addiction, also serve to a variety of essential endoge¬nous functions. Altering functions of these pathways may cause side effect which limit the use of these drugs which also have a high relapse ratio. The limitation of previous nicotine dependence treatments, create a need for new treatment options. One of the newest approaches is immunization against nicotine. The aim of this treatment, is to prevent nicotine from entering the brain, where it exerts its reinforcing effects.
Bookmark/Search this post with
Abstract (Original Language): 
Madde bağımlılığı; kronik, tekrarlayan bir beyin hastalığıdır. Sigara içilmesi ile ilişkili hastalıklar, en fazla ölüme yol açan önlenebilir nedenlerden biridir. Tütünün içinde birinci derecede bağımlılık yapan etken madde nikotindir. Nikotin; beyinde, bağımlılığa yol açan birçok etkiye neden olur. Nikotin bağımlılığı ile ilişkili nöral yollar, birçok endojen fonksiyonda da görev alır. Tütün bağımlılığı, bu nöral yolları etkileyerek tedavi edilirken, birçok yanetkinin ortaya çıkması, bu tür ilaçların kullanımını kısıtlamaktadır. Üstelik bu ilaçlarla yüksek nüks oranları görülür. Nikotin bağımlılık tedavi¬lerinin kısıtlılıkları ve yetersizlikleri yeni tedavi seçeneklerine ihtiyaç doğurmaktadır. Nikotine karşı bağışıklarına, bu alandaki en yeni yaklaşımlardan biridir. Bu tedavinin amacı; nikotinin, pekiştirici etkisinin beyne ulaşmasını engellemektir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_10_pp_75-78.pdf
  • 2
75-78
  • Turkish

REFERENCES

References: 

1. Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994; 309(6959): 937-9.
2. Stolerman IP, Goldfarb T, Fink R, Jarvik ME. Influencing cigarette smoking with nicotine antagonists. Psychopharmacologia 1973; 28: 247-59.
3. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. JNeurobiol 2002; 53: 606-17.
4. A US Public Health Service Report. A clinical practice guideline for treating tobacco use and dependence. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. Jama
2000; 283: 3244-54.
5. Jenner E. An inquiry into the causes and effects of the Variolae Vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow-pox. 3. Baskı London: printed for the author by D.N.Shury, 1801. http://www.sc.edu/library/spcoll/ nathist/jenner2.html adresinden 13/02/2006 tarihinde erişilmiştir.
6. Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005; 108: 76-85.
7. Lutwick LI. Unconventional vaccine targets. Immunization for pregnancy, peptic ulcer, gastric cancer, cocaine abuse, and atherosclerosis. InfectDis Clin North Am 1999; 13: 245-64.
8. Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunophar-macol 2000; 22: 809-19.
9. Pentel PR, Malin DH, Ennifar S ve ark. A nicotine conjugate vaccine redu¬ces nicotine distribution to brain and attenuates its behavioral and cardiovas¬cular effects in rats. Pharmacol Biochem Behav 2000; 65:191-8.
10. Owens SM, Mayersohn M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986;14: 52-8.
11. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. Changes in heroin self-administration by a rhesus monkey after morphine immunisati¬on. Nature 1974; 252(5485): 708-10.
12. Owens SM, Mayersohn M. Modulation of phencyclidine (PCP) pharmacokinetics with PCP-specific Fab fragments. NIDA Res Monogr 1986; 64: 112¬26.
13. Henningfield JE, Goldberg SR. Nicotine as a reinforcer in human subjects and laboratory animals. Pharmacol Biochem Behav 1983; 19: 989-92.
14. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liabili¬ty. J Consult Clin Psychol 1993; 61: 743-50.
15. Palmer KJ, Buckley MM, Faulds D. Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44: 498-529.
16. Vocci FJ, Chiang CN. Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs 2001; 15: 505-14.
17. de Villiers SH, Lindblom N, Kalayanov G ve ark. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nuc¬leus accumbens shell. Respiration 2002; 69: 247-53.
18. Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM. Generation of an-ti(+)methamphetamine antibodies is not impeded by (+) methamphetamine administration during active immunization of rats. Int Immunopharmacol
2001; 1: 329-38.
19. Hieda Y, Keyler DE, Vandevoort JT ve ark. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997; 283:
1076-81.
20. Hieda Y, Keyler DE, VanDeVoort JT ve ark. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl) 1999; 143: 150-7.
21. Keyler DE, Shoeman D, LeSage MG, Calvin AD, Pentel PR. Maternal
vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J Pharmacol Exp Ther 2003; 305: 587-92.
22. Chornock WM, Stitzer ML, Gross J, Leischow S. Experimental model of
smoking re-exposure: effects on relapse. Psychopharmacology (Berl)
1992;108: 495-500.
23. Lesage MG, Keyler DE, Hieda Y ve ark. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 2005: 1-8.
24. Keyler DE, Dufek MB, Calvin AD ve ark. Reduced nicotine distribution from mother to fetal brain in rats vaccinated against nicotine: time course and influence of nicotine dosing regimen. Biochem Pharmacol 2005; 69: 1385¬95.
25. Cohen PJ. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug Alcohol Depend 1997; 48: 167-74.
26. Hall W. The prospects for immunotherapy in smoking cessation. Lancet
2002; 360(9339): 1089-91.
27. Hasman A, Holm S. Nicotine conjugate vaccine: is there a right to a smok¬ing future? J Med Ethics 2004; 30: 344-5.
28. Kantak KM. Vaccines against drugs of abuse: a viable treatment option?
Drugs 2003; 63: 341-52.
29. Thomas GA, Rhodes J, Green JT, Richardson C. Role of smoking in inf¬lammatory bowel disease: implications for therapy. Postgrad Med J 2000;
76(895): 273-9.
30. Benowitz NL, Hall SM, Herning RI, Jacob P, 3rd, Jones RT, Osman AL.
Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med
1983; 309: 139-42.

Thank you for copying data from http://www.arastirmax.com